Trend of A-share and Hong Kong stock innovative medicine plate this week
In the fourth week of December 2021, a total of 21 stocks in the mainland and Hong Kong innovative drugs sector rose and 26 stocks fell. Among them, the top three gainers were Yaoming junuo-b (+ 35.89%), Chuangsheng group-B (+ 25.89%), tengshengbo medicine-b (+ 16.52%). The top three gainers were Fuhong hanlin-b (- 13.10%), Yunding xinyao-b (- 13.09%) and Rongchang biology-b (- 12.57%). This week, the A-share innovative drug sector rose 0.6%, outperforming the CSI 300 index by 1.28pp, and the biomedicine sector fell 3.49%. In the past six months, the A-share innovative drug sector fell 19.93%, outperforming the CSI 300 index by 13.81pp, and the biomedicine sector fell 27.49%. This week, the Hong Kong stock innovative drug sector rose 0.65%, outperformed the Hang Seng Index by 0.51pp, and the Hang Seng healthcare sector fell 2.02%. In the past six months, Hong Kong Shares of innovative drugs fell 31.92%, underperforming the Hang Seng Index by 9.65pp, and Hang Seng healthcare fell 52.65%.
Progress of key innovative drugs in China
In December, 11 new drugs were approved for marketing in China. This week, three new drugs were approved to go on the market for the first time, including Novartis’s alpha tomumab, cornerstone pharmaceutical’s shugli mAb and Pfizer’s izumab oxamicin.
Progress of overseas key innovative drugs
In December, 14 new drugs were approved by FDA. Three new drugs were approved this week, VIV healthcare’s apretude, which was approved for pre exposure prevention of HIV. Rivaroxaban of Janssen Pharms is used for two new pediatric indications: the treatment of venous thromboembolism (VTE) and the prevention of thrombosis in patients with congenital heart disease who underwent Fontan surgery aged 2 years and over. Leqvio (inclisiran) of Novartis is used for the treatment of atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (FH) patients. In December, five new drugs were approved for marketing in Europe. This week, one new drug was approved, and the covid-19 vaccine nvx-cov2373 of Novax pharmaceutical company obtained the conditional marketing license granted by European EMA.
Weekly special topic – research and development progress of Pd / L1 + CTLA4 dual target drugs
CTLA-4 antibody can block the negative regulation of immune response and make the immune response continue. CTLA-4 and Pd / L1 are different immune checkpoints. Blocking these two targets at the same time can obtain better effects than single drugs. At present, several double target drugs are under research. There are 15 Pd / L1 + CTLA4 dual target projects under research in the world, most of which are dual antibodies. The double antibodies are anti-pd1 / CTLA4 bispecific antibodies represented by kadonilimab of kangfang biology and anti-pdl1 / CTLA4 bispecific antibodies represented by kn046 of Corning Jerry.
Progress of global key innovative drug transactions this week
This week, there were 21 key transactions in the world, and 10 key transactions with disclosed amount. Baiji Shenzhou, Novartis, tianlishi, LVYE pharmaceutical, Gaocheng biology, Frontier Biotechnologies Inc(688221) , Dongyao pharmaceutical and Xinyue biology all have transactions.
Risk warning: expected risk of drug price reduction; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure
